- Home
- LSF vs VYNE Comparison
LSF vs VYNE Comparison
Compare LSF & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LSF | VYNE |
|---|---|---|
| Founded | 2015 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.8M | 20.0M |
| IPO Year | 2020 | 2017 |
Fundamental Metrics
Financial Performance| Metric | LSF | VYNE |
|---|---|---|
| Price | $2.69 | $0.61 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $12.00 | N/A |
| AVG Volume (30 Days) | 66.9K | ★ 369.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.28 | 33.33 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $43,295,137.00 | N/A |
| Revenue This Year | $15.87 | N/A |
| Revenue Next Year | $14.98 | $16.67 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 26.50 | N/A |
| 52 Week Low | $1.98 | $0.29 |
| 52 Week High | $7.94 | $2.57 |
Technical Indicators
Market Signals| Indicator | LSF | VYNE |
|---|---|---|
| Relative Strength Index (RSI) | 44.30 | 63.76 |
| Support Level | $2.46 | $0.55 |
| Resistance Level | $2.76 | $0.75 |
| Average True Range (ATR) | 0.22 | 0.02 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 34.68 | 98.91 |
Price Performance
Historical ComparisonAbout LSF Laird Superfood Inc.
Laird Superfood Inc is engaged in the business of manufacturing and marketing differentiated plant-based and functional foods. The product portfolio includes Coffee creamers, Hydration products and beverage-enhancing supplements, Harvest snacks and various other food items, and Coffee, tea, and hot chocolate products.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.